Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- and High-Risk Prostate Cancer Across the United States

JAMA Oncol. 2016 Sep 1;2(9):1236-8. doi: 10.1001/jamaoncol.2016.1143.

Authors

Aaron D Falchook¹, Ramsankar Basak¹, Jahan J Mohiuddin¹, Ronald C Chen²

Affiliations

¹ Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill.
² Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill2University of North Carolina-Lineberger Comprehensive Cancer Center, Chapel Hill.

PMID: 27367418
DOI: 10.1001/jamaoncol.2016.1143

No abstract available

MeSH terms

Androgen Antagonists / therapeutic use*
Combined Modality Therapy
Databases, Factual
Geography
Humans
Male
Multivariate Analysis
Neoplasm Grading
Odds Ratio
Practice Patterns, Physicians' / statistics & numerical data*
Prostatic Neoplasms / pathology
Prostatic Neoplasms / therapy*
Radiotherapy / statistics & numerical data*
Radiotherapy Dosage
United States

Substances

Androgen Antagonists